New treatment approach for high-grade serous ovarian cancer using combination therapy
Development of a first-in-class combination of DNA damage response inhibitors for the treatment of high-grade serous ovarian cancer
This study is looking at a new treatment for high-grade serous ovarian cancer that could help patients with certain genetic changes, aiming to make existing therapies work better and improve outcomes for those affected.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aprea Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10784732 on NIH RePORTER |
What this research studies
This research focuses on developing a novel combination therapy for high-grade serous ovarian cancer (HGSOC), particularly targeting tumors with BRCA1/2 mutations and those overexpressing Cyclin E. The approach involves using a combination of WEE1 kinase inhibitors and ATR inhibitors to overcome resistance to existing treatments like PARP inhibitors. By understanding the molecular mechanisms behind tumor responses, the research aims to improve treatment efficacy and patient outcomes. Patients with specific genetic profiles may benefit from this innovative therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with high-grade serous ovarian cancer, particularly those with BRCA1/2 mutations or those whose tumors overexpress Cyclin E.
Not a fit: Patients with low-grade serous ovarian cancer or those without the specific genetic mutations targeted by this research may not benefit.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with high-grade serous ovarian cancer, potentially improving survival rates.
How similar studies have performed: Previous research has shown promising results with similar combination therapies in other cancer types, indicating potential for success in this novel approach.
Where this research is happening
Boston, United States
- Aprea Therapeutics, INC. — Boston, United States (Active)
Researchers
- Principal investigator: Gilad, Oren — Aprea Therapeutics, INC.
- Study coordinator: Gilad, Oren
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.